May 3, 2022
Alon Ben-Noon is the Co-Founder and CEO of NeuroSense Therapeutics, which is working on ALS therapy and other neurodegenerative diseases like Parkinson's and Alzheimer's disease. They are working on a disease-modifying drug PrimeC and have identified a large set of biomarkers that are related to ALS progression and the...
May 3, 2022
Alon Ben-Noon is the Co-Founder and CEO of NeuroSense Therapeutics, which is working on ALS therapy and other neurodegenerative diseases like Parkinson's and Alzheimer's. They are working on a disease-modifying drug PrimeC and have identified a large set of biomarkers that are related to ALS progression and the...
Apr 20, 2022
Dr. Travis Mickle is the President and CEO of KemPharm, a clinical clinical-stage specialty pharmaceutical company. KemPharm is building on their successful launch of AZSTARYS for ADHD to treat rare sleep disorders like idiopathic hypersomnia as well as sleep disorders that are a symptom of diseases like Alzheimer's and...
Apr 20, 2022
Dr. Travis Mickle is the President and CEO of KemPharm, a clinical clinical-stage specialty pharmaceutical company. KemPharm is building on their successful launch of AZSTARYS for ADHD to treat rare sleep disorders like idiopathic hypersomnia as well as sleep disorders that are a symptom of diseases like Alzheimer's and...
Mar 8, 2022
Paula Ragan is the CEO and President of X4 Pharmaceuticals, which focuses on the rare disease WHIM Syndrome. Patients have a deficiency in their immune system, and as a result, this diminishes their ability to fight chronic infections, and they have a higher risk for severe cancers.
Paula explains, "If one thinks about...